For the years ended December 31, 2018,
2017 and 2016, we have recognized no revenues from this arrangement.
Anti-Tau antibody in AD – 2012 agreement
In June 2012, we entered into a second
agreement with Genentech to commercialize anti-Tau antibodies for use as immunotherapeutics. The value of this exclusive, worldwide
alliance is potentially greater than CHF 400 million and includes upfront and clinical, regulatory and commercial milestone payments.
In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits
to the high-single digits. The agreement also provides for collaboration on two additional indications built on the same anti-Tau
antibody program as well as potential anti-Tau diagnostic products.
The term of the Agreement commenced on
the Effective Date and, unless sooner terminated by mutual agreement or pursuant to any other provision of the Agreement, terminates
on the date on which all obligations between the Parties with respect to the payment of milestones or royalties with respect to
Licensed Products have passed or expired. Either party may terminate the Agreement for any material breach by the other Party,
provided a cure period of 90 days from the date notice is given.
To date, we have received payments totaling
CHF 59 million, including a CHF 14 million milestone payment received and recognized in the fourth quarter of 2017 associated
with the first patient dosing in a Phase 2 clinical trial for Alzheimer’s disease with an anti-Tau monoclonal body known
as RG6100, a CHF 14 million milestone payment recognized in the second quarter of 2016 and received in July 2016, associated with
the announcement of the commencement of the Phase 1 clinical study of the lead anti-Tau antibody candidate and a CHF 14 million
milestone payment received in 2015 in connection with the ED-GO decision. As we met all performance obligations on reaching these
milestones, we have recognized revenue in the respective periods.
AC Immune assessed this arrangement in
accordance with IFRS 15 and concluded that Genentech is a customer. The Company identified the following performance obligations
under the contract: (i) a right-to-use license and (ii) conduct research under a research plan. The Company considered the research
and development capabilities of Genentech and Genentech’s right to sublicense to conclude that the license has stand-alone
functionality and is distinct. The Company’s obligation to perform research does not significantly impact or modify
the licenses’ granted functionality.
At execution of the agreement, the transaction
price included CHF 17 million up-front consideration received. At inception, none of the clinical or regulatory milestones
had been included in the transaction price, as all milestone amounts were fully constrained. The Company has received three milestones
since inception totaling CHF 42 million. The Company could also receive up to an additional CHF 368.5 million in clinical, regulatory
and commercial milestones. In assessing that future clinical, regulatory or commercial milestones are fully constrained, the Company
considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon
success in future clinical trials. Any consideration related to sales-based milestones (including royalties) will be recognized
when the related sales occur as they were determined to relate predominantly to the license granted to Genentech and therefore
have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period
and as uncertain events are resolved or other changes in circumstances occur.
For the years ended December 31, 2018,
2017 and 2016, we have recognized nil, CHF 14 million and CHF 14 million from this arrangement, respectively.
Tau Vaccine in AD – 2014 agreement with
In December 2014, we entered into an agreement
with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize
therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The value of this partnership is potentially
up to CHF 500 million and includes upfront and clinical, regulatory and commercial milestones. We and Janssen will co-develop the
two second generation lead therapeutic vaccines, ACI-35.030 and JACI-35.054, through Phase 1b/2a completion. From Phase 2b and
onwards, Janssen will assume responsibility for the clinical development,